These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 20587042)

  • 1. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
    Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
    BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis.
    Yamaguchi N; Fujii T; Aoi S; Kozuch PS; Hortobagyi GN; Blum RH
    Eur J Cancer; 2015 Nov; 51(16):2314-20. PubMed ID: 26343314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 May; 2010(5):CD005006. PubMed ID: 20464735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2010 Mar; (3):CD005006. PubMed ID: 20238335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Kremer LC
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
    Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
    J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
    Mao Z; Shen K; Zhu L; Xu M; Yu F; Xue D; Li H; Xue C
    Oncol Res Treat; 2019; 42(7-8):405-413. PubMed ID: 31104059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer.
    Ghasemi K; Vaseghi G; Mansourian M
    J Oncol Pharm Pract; 2021 Mar; 27(2):414-427. PubMed ID: 33081570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
    Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
    Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
    Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
    Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
    Xu L; Long Y; Tang X; Zhang N
    Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity.
    Kheiri B; Abdalla A; Osman M; Haykal T; Chahine A; Ahmed S; Osman K; Hassan M; Bachuwa G; Bhatt DL
    Am J Cardiol; 2018 Dec; 122(11):1959-1964. PubMed ID: 30292333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
    Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
    Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis.
    Alizadehasl A; Ghadimi N; Kaveh S; Maleki M; Ghavamzadeh A; Noohi F; Hosseinifard H
    Int J Clin Pharm; 2021 Feb; 43(1):25-34. PubMed ID: 32910372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
    Mo Z; Deng Y; Bao Y; Liu J; Jiang Y
    Cancer Med; 2023 Dec; 12(24):21709-21724. PubMed ID: 38054208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.